HOME >> MEDICINE >> NEWS
Antidepressant does not improve symptoms in advanced cancer patients without major depression

The established antidepressant sertraline does not improve symptoms, wellbeing or survival in patients with advanced cancer who do not have major depression. The findings are reported early Online - timed to coincide with presentation of the paper at the American Society of Clinical Oncology meeting in Chicago and in the July edition of The Lancet Oncology.

Self-ratings of depression, mood, fatigue, and quality of life are significant predictors of survival in patients with advanced cancer. Although the simple explanation for this is that people close to death get very depressed, two previous small randomised trials showed substantial survival benefits with psychological treatments aimed to improve wellbeing. Therefore Dr Martin Stockler, National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Australia, and colleagues assessed the benefit on symptoms and survival of sertraline in patients with advanced cancer but no major depression.

The authors say: We postulated that sertraline might improve these features of health-related quality of life and increase overall survival by helping patients to cope better with their illness and treatment.

Between 2001 and 2006, the researchers treated 189 patients with advanced cancer with 50mg sertraline each day, or placebo. They found that patients receiving sertraline experienced no significant effect on depression, anxiety, fatigue, wellbeing or quality of life. Their findings suggest the overmedicalisation (giving drugs to patients where the benefit is unclear or unproven) of patients with advanced cancer should be avoided.

However, the authors stress that sertraline use should continue in situations where it is of proven benefit such as patients with advanced cancer who have major depression.

They conclude: Treatment with a selective serotonin reuptake inhibitor [antidepressant] should be reserved for those with a proven indica
'"/>

Contact: Dr. Martin Stockler
stockler@med.usyd.edu.au
Lancet
3-Jun-2007


Page: 1 2

Related medicine news :

1. Antidepressants safe for children and adolescents
2. Antidepressants improve post-stroke thinking outside the box
3. CIHR-funded research: Antidepressants help men decrease alcohol consumption, but not women
4. Antidepressants associated with increased risk for suicide attempts, decreased risk for death
5. Antidepressant drug may prevent recurrence of depression in patients with diabetes
6. Antidepressant medication may prevent recurring depression in diabetics
7. Antidepressants might reduce risk of colorectal cancer
8. Antidepressants may be associated with modestly increased risk of suicidality in children
9. Antidepressant use during pregnancy appears associated with withdrawal symptoms in newborns
10. Antidepressant therapy for major depression in children and adolescents
11. Antidepressants and electroconvulsive therapy are the best treatment options for depression

Post Your Comments:
(Date:3/6/2015)... Protein identification is increasingly being ... science research including drug discovery, diagnostics, immunology and ... was valued at $1,569.00 million in 2014 and ... 10.63% to reach $2,600.28 million in 2019. , ... protein based on protein size, shape, sequence and ...
(Date:3/6/2015)... As healthcare providers create one ... from disparate systems, they are using OnBase by ... efficiency. Enterprise content management (ECM) solutions ... IT solutions, including electronic medical records (EMR), enterprise ... , The following organizations have recently integrated ...
(Date:3/6/2015)... March 06, 2015 Saving Moses, a ... the world is traveling to Angola, Africa March 7-14 ... their malnutrition program. , This will be the organizations ... Angola, demonstrating their commitment to the region’s population by ... team will engage with the mothers and babies of ...
(Date:3/6/2015)... 06, 2015 Follow us on ... pharmacokinetics of a drug refers to testing of absorption, ... an organism. When toxicity studies are clubbed together with ... ADME/Tox. Increasing focus on lowering costs and time during ... worldwide. The traditional drug development model uses toxicity and ...
(Date:3/6/2015)... March 06, 2015 “On Tap” takes the ... the grand stage, to the silver screen and to modern ... precision toe-tapping numbers and their famous eye-high kicks! Producers, directors ... rich history of tap dancing in this robust show, showcasing ... of the United States. , “On Tap” is proud ...
Breaking Medicine News(10 mins):Health News:Protein Identification Market worth $2,600.28 Million By 2019 - New Research Report by MarketsandMarkets 2Health News:Protein Identification Market worth $2,600.28 Million By 2019 - New Research Report by MarketsandMarkets 3Health News:Healthcare Providers Select OnBase by Hyland to Improve Patient Care and Streamline Administrative Departments 2Health News:Healthcare Providers Select OnBase by Hyland to Improve Patient Care and Streamline Administrative Departments 3Health News:Saving Moses Returns to Angola to Continue Giving Infants and Children a Chance to Live 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2
(Date:3/6/2015)... , March 6, 2015  Palatin Technologies, Inc. (NYSE MKT: ... 27 th Annual ROTH Conference on Wednesday, March 11, ... held at the Ritz Carlton Laguna Niguel in ... Spana , Ph.D., President and Chief Executive Officer of Palatin ... programs. About Palatin Technologies, Inc. ...
(Date:3/6/2015)... , March 6, 2015   Hospira, Inc. ... Food and Drug Administration (FDA) on today,s FDA approval of ... . This is a watershed moment for improving patient access ... leading global provider of biosimilars, Hospira has seen first-hand the ... a proud participant in these early stages of the development ...
(Date:3/6/2015)... March 6, 2015  Aethlon Medical, Inc. (OTCQB:AEMD), the ... diseases and cancer, today announced that James A. ... present a corporate overview at the 27th Annual ROTH ... time.  Aethlon was previously scheduled to present at 5:30 ... will be held at The Ritz-Carlton Hotel in ...
Breaking Medicine Technology:Hospira Statement on FDA Approval of the First Biosimilar in the United States 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 3Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference 2
Cached News: